Treatment for C3 glomerulopathy involves a combination of medications and lifestyle changes to manage the symptoms and prevent or slow kidney damage. There isn’t a cure for this rare disease, but ...

Pegcetacoplan (Empaveli) reduced proteinuria and helped stabilize kidney function in patients with C3 glomerulopathy or immune-complex membranoproliferative glomerulonephritis (MPGN). The C3 and C3b ...

Iptacopan is the first FDA-approved treatment for C3G, targeting the disease's underlying cause by inhibiting the alternative complement pathway. The phase 3 APPEAR-C3G study showed a 35.1% reduction ...

C3 glomerulopathy (C3G) and primary immune complex membranoproliferative glomerulonephritis (IC-MPGN) are two rare kidney diseases. They’re both driven by activity of the complement system, which is a ...

The change in proteinuria was significantly greater with pegcetacoplan than placebo, representing a 68.1% relative reduction vs placebo. HealthDay News — Among patients with C3 glomerulopathy or ...

Please provide your email address to receive an email when new articles are posted on . Pegcetacoplan was associated with a 68.3% reduction in proteinuria at 26 weeks vs. placebo. Of patients treated ...

SAN DIEGO — The investigational drug pegcetacoplan, a C3/C3b inhibitor, showed significant benefits in the treatment of patients with C3 glomerulopathy or primary immune complex–mediated ...

C3G and IgAN are both rare forms of chronic kidney disease affecting the glomeruli, the kidney’s blood filters, but they arise from different immune system issues. Both conditions are immune-mediated ...

Iptacopan treatment on top of standard of care resulted in significant and clinically meaningful reductions in proteinuria compared with placebo in patients with complement 3 glomerulopathy. Results ...

PASADENA, Calif.--(BUSINESS WIRE)--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced topline results from Part 2 of a Phase 1/2 clinical study of ARO-C3, the company’s investigational RNA ...